{"id":71079,"date":"2026-04-14T16:16:54","date_gmt":"2026-04-14T10:46:54","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=71079"},"modified":"2026-04-14T16:16:56","modified_gmt":"2026-04-14T10:46:56","slug":"dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/","title":{"rendered":"Dr. Lal Path Labs Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook"},"content":{"rendered":"<p>Dr. Lal Path Labs (NSE: LALPATHLAB) is scheduled to declare its Q4 FY26 results on May 8, 2026, when the board of directors will approve the audited financial statements for the January\u2013March 2026 quarter and the full year FY2025\u201326. The stock trades at Rs 2,350 as of April 2026 \u2014 down -20% from its 52-week high of Rs 2,950 \u2014 making this a closely watched quarter for investors assessing whether the correction represents opportunity or ongoing fundamental pressure.<\/p><p>This Q4 FY26 results preview for Dr. Lal Path Labs covers the confirmed results date, analyst consensus estimates, five key performance factors, five risks to monitor, analyst ratings, and the complete share price outlook. Q4 FY26 is particularly significant as it delivers the full-year FY26 results alongside the first management commentary on FY27 business outlook.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Get free investment predictions from SEBI-registered analysts on Univest<\/strong><\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Dr_Lal_Path_Labs_Q4_Results_2026_Date\" title=\"Dr. Lal Path Labs Q4 Results 2026 Date\">Dr. Lal Path Labs Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Why_Q4_FY26_Matters\" title=\"Why Q4 FY26 Matters\">Why Q4 FY26 Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Dr_Lal_Path_Labs_Q4_FY26_Earnings_Estimates\" title=\"Dr. Lal Path Labs Q4 FY26 Earnings Estimates\">Dr. Lal Path Labs Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#5_Key_Factors_Driving_Dr_Lal_Path_Labs_Q4_FY26_Performance\" title=\"5 Key Factors Driving Dr. Lal Path Labs Q4 FY26 Performance\">5 Key Factors Driving Dr. Lal Path Labs Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#1_India_Branded_Generic_Growth\" title=\"1. India Branded Generic Growth\">1. India Branded Generic Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#2_Export_Market_Development\" title=\"2. Export Market Development\">2. Export Market Development<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#3_New_Product_Launches\" title=\"3. New Product Launches\">3. New Product Launches<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#4_Field_Force_Productivity\" title=\"4. Field Force Productivity\">4. Field Force Productivity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#5_Raw_Material_API_Costs\" title=\"5. Raw Material API Costs\">5. Raw Material API Costs<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#5_Risks_to_Watch_in_Dr_Lal_Path_Labs_Q4_FY26\" title=\"5 Risks to Watch in Dr. Lal Path Labs Q4 FY26\">5 Risks to Watch in Dr. Lal Path Labs Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Risk_1_Input_Cost_Volatility\" title=\"Risk 1: Input Cost Volatility\">Risk 1: Input Cost Volatility<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Risk_2_Revenue_Concentration_Risk\" title=\"Risk 2: Revenue Concentration Risk\">Risk 2: Revenue Concentration Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Risk_3_Competitive_Pressure\" title=\"Risk 3: Competitive Pressure\">Risk 3: Competitive Pressure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Risk_4_Regulatory_Environment\" title=\"Risk 4: Regulatory Environment\">Risk 4: Regulatory Environment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Risk_5_Macroeconomic_Sensitivity\" title=\"Risk 5: Macroeconomic Sensitivity\">Risk 5: Macroeconomic Sensitivity<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Dr_Lal_Path_Labs_Share_Price_and_Analyst_Ratings\" title=\"Dr. Lal Path Labs Share Price and Analyst Ratings\">Dr. Lal Path Labs Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Q_When_is_Dr_Lal_Path_Labs_Q4_results_2026_date\" title=\"Q: When is Dr. Lal Path Labs Q4 results 2026 date?\">Q: When is Dr. Lal Path Labs Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Q_What_is_Dr_Lal_Path_Labs_Q4_FY26_revenue_estimate\" title=\"Q: What is Dr. Lal Path Labs Q4 FY26 revenue estimate?\">Q: What is Dr. Lal Path Labs Q4 FY26 revenue estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Q_What_is_Dr_Lal_Path_Labs_Q4_FY26_PAT_estimate\" title=\"Q: What is Dr. Lal Path Labs Q4 FY26 PAT estimate?\">Q: What is Dr. Lal Path Labs Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Q_Will_Dr_Lal_Path_Labs_declare_a_dividend_in_Q4_FY26\" title=\"Q: Will Dr. Lal Path Labs declare a dividend in Q4 FY26?\">Q: Will Dr. Lal Path Labs declare a dividend in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Q_What_is_Dr_Lal_Path_Labs_current_share_price\" title=\"Q: What is Dr. Lal Path Labs current share price?\">Q: What is Dr. Lal Path Labs current share price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Q_What_were_Dr_Lal_Path_Labs_Q3_FY26_results\" title=\"Q: What were Dr. Lal Path Labs Q3 FY26 results?\">Q: What were Dr. Lal Path Labs Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Q_When_do_TCS_and_Infosys_announce_Q4_results_2026\" title=\"Q: When do TCS and Infosys announce Q4 results 2026?\">Q: When do TCS and Infosys announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Q_Is_Dr_Lal_Path_Labs_a_good_investment_ahead_of_Q4_results\" title=\"Q: Is Dr. Lal Path Labs a good investment ahead of Q4 results?\">Q: Is Dr. Lal Path Labs a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-path-labs-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dr_Lal_Path_Labs_Q4_Results_2026_Date\"><\/span><strong>Dr. Lal Path Labs Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>The Dr. Lal Path Labs Q4 FY26 results date is May 8, 2026. The board of directors meeting will approve the quarter and full-year FY26 financial results, consider a final dividend recommendation for FY26, and provide management guidance for FY27.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Q4 Results Date<\/strong><\/td><td><strong>Key Metric to Watch<\/strong><\/td><\/tr><tr><td>[object Object]<\/td><td>April 9, 2026 (Declared)<\/td><td>FY27 CC guidance + deal TCV<\/td><\/tr><tr><td>[object Object]<\/td><td>April 23, 2026<\/td><td>CC revenue growth guidance<\/td><\/tr><tr><td>Bharti Airtel<\/td><td>April 29, 2026<\/td><td>ARPU + 5G subscribers<\/td><\/tr><tr><td>Dr. Lal Path Labs<\/td><td>May 8, 2026<\/td><td>Test volume + EBITDA margin<\/td><\/tr><tr><td>Dr. Lal Path Labs<\/td><td>May 8, 2026<\/td><td>See estimates below<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_Q4_FY26_Matters\"><\/span><strong>Why Q4 FY26 Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Q4 (January\u2013March 2026) is the final quarter of FY2025\u201326 and carries the highest informational weight of any quarterly result. Beyond the Q4 standalone performance, investors receive: the complete FY26 annual revenue, PAT, and margin profile; management&#8217;s first formal FY27 revenue and margin guidance; the final dividend recommendation; and qualitative commentary on demand environment and competitive dynamics entering the new fiscal year.<\/p><p>For Dr. Lal Path Labs specifically, Q4 captures the peak-season dynamics of the Diagnostics \/ Healthcare sector \u2014 a quarter where operating leverage typically manifests most visibly if demand conditions are favourable.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dr_Lal_Path_Labs_Q4_FY26_Earnings_Estimates\"><\/span><strong>Dr. Lal Path Labs Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155637\/image-745-1024x536.jpeg\" alt=\"Dr. Lal Path Labs Q4 FY26 Earnings Estimates\" class=\"wp-image-71080\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155637\/image-745-1024x536.jpeg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155637\/image-745-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155637\/image-745-768x402.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155637\/image-745-900x471.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155637\/image-745-600x314.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155637\/image-745-150x79.jpeg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155637\/image-745.jpeg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Dr. Lal Path Labs Q4 FY26 analyst consensus estimates \u2014 Revenue, PAT, Margin | univest.in<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Access premium analyst research on Univest<\/strong><\/a>.<\/p><p>Based on publicly available analyst consensus data, the following are the Q4 FY26 estimates for Dr. Lal Path Labs:<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>QoQ Trend<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 620 Cr<\/td><td>Rs 554 Cr<\/td><td>Sequential improvement expected<\/td><\/tr><tr><td>Net Profit (PAT)<\/td><td>Rs 88 Cr<\/td><td>Rs 79 Cr<\/td><td>Normalisation in progress<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 24%<\/td><td>Q3 FY26 level<\/td><td>Stable to improving<\/td><\/tr><tr><td>Volume \/ Growth Driver<\/td><td>+12% volume YoY<\/td><td>Prior quarter<\/td><td>YoY comparison<\/td><\/tr><tr><td>Final Dividend (Expected)<\/td><td>Rs 15<\/td><td>FY26 interim dividends<\/td><td>Board decision<\/td><\/tr><\/tbody><\/table><\/figure><p>Screen <strong>Dr. Lal Path Labs<\/strong> live on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a> \u2014 real-time fundamentals, FII\/DII flows, and analyst ratings.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> for real-time Q4 result alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_Driving_Dr_Lal_Path_Labs_Q4_FY26_Performance\"><\/span><strong>5 Key Factors Driving Dr. Lal Path Labs Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_India_Branded_Generic_Growth\"><\/span><strong>1. India Branded Generic Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>India pharmaceutical market (IPM) growing at 8\u201310% annually. Q4 captures year-end prescription momentum and seasonal demand for respiratory and anti-infective products.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Export_Market_Development\"><\/span><strong>2. Export Market Development<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Regulated market (US, EU) and emerging market (Africa, CIS) export revenue diversifies beyond the domestic market and typically carries higher margins.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_New_Product_Launches\"><\/span><strong>3. New Product Launches<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>ANDA approvals, new molecule registrations, and brand extensions expand the addressable market within existing therapeutic areas.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Field_Force_Productivity\"><\/span><strong>4. Field Force Productivity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Medical representative (MR) productivity and coverage quality determine prescription generation. Management commentary on field force efficiency is a key quality indicator.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Raw_Material_API_Costs\"><\/span><strong>5. Raw Material API Costs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>API (Active Pharmaceutical Ingredient) procurement costs, which depend on Chinese API pricing and domestic manufacturing capacity, determine gross margin trajectory.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Dr_Lal_Path_Labs_Q4_FY26\"><\/span><strong>5 Risks to Watch in Dr. Lal Path Labs Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_1_Input_Cost_Volatility\"><\/span><strong>Risk 1: Input Cost Volatility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Raw material and input cost changes can compress margins unexpectedly within a quarter.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_2_Revenue_Concentration_Risk\"><\/span><strong>Risk 2: Revenue Concentration Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Customer or geographic concentration creates quarterly revenue variance risk.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_3_Competitive_Pressure\"><\/span><strong>Risk 3: Competitive Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Market competition in the Diagnostics \/ Healthcare sector may intensify, requiring additional price or volume concessions.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_4_Regulatory_Environment\"><\/span><strong>Risk 4: Regulatory Environment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Policy and regulatory changes affecting the sector can create revenue or compliance cost risks.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_5_Macroeconomic_Sensitivity\"><\/span><strong>Risk 5: Macroeconomic Sensitivity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Global and domestic macroeconomic conditions \u2014 tariffs, interest rates, consumption trends \u2014 affect end-market demand.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dr_Lal_Path_Labs_Share_Price_and_Analyst_Ratings\"><\/span><strong>Dr. Lal Path Labs Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155638\/image-746-1024x536.jpeg\" alt=\"Dr. Lal Path Labs Share Price and Analyst Ratings\" class=\"wp-image-71081\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155638\/image-746-1024x536.jpeg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155638\/image-746-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155638\/image-746-768x402.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155638\/image-746-900x471.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155638\/image-746-600x314.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155638\/image-746-150x79.jpeg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155638\/image-746.jpeg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Dr. Lal Path Labs share price and analyst ratings \u2014 Q4 FY26 preview | univest.in<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Parameter<\/strong><\/td><td><strong>Value<\/strong><\/td><\/tr><tr><td>CMP (April 2026)<\/td><td>Rs 2,350<\/td><\/tr><tr><td>52-Week High<\/td><td>Rs 2,950<\/td><\/tr><tr><td>52-Week Low<\/td><td>Rs 2,050<\/td><\/tr><tr><td>1-Year Return<\/td><td>-20%<\/td><\/tr><tr><td>Market Capitalisation<\/td><td>Rs 19,800 Cr<\/td><\/tr><tr><td>Sector<\/td><td>Diagnostics \/ Healthcare<\/td><\/tr><tr><td>NSE Ticker<\/td><td>LALPATHLAB<\/td><\/tr><tr><td>Q4 Results Date<\/td><td>May 8, 2026<\/td><\/tr><\/tbody><\/table><\/figure><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Thesis Summary<\/strong><\/td><\/tr><tr><td>Motilal Oswal<\/td><td>BUY<\/td><td>Q4 recovery potential; sector tailwinds intact<\/td><\/tr><tr><td>YES Securities<\/td><td>ADD<\/td><td>Earnings inflection expected; watch Q4 guidance<\/td><\/tr><tr><td>Kotak Institutional<\/td><td>NEUTRAL<\/td><td>Fair valued at current levels; execution key<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Dr. Lal Path Labs Q4 FY26 results on May 8, 2026 will be the most important quarterly event of FY26. At Rs 2,350 \u2014 down -20% from its 52-week high of Rs 2,950 \u2014 the stock enters results season having already priced in significant headwinds. Revenue above Rs 620 Cr with EBITDA 24% would constitute a beat relative to current analyst consensus. Management&#8217;s FY27 guidance on 12% volume YoY trajectory will be the primary re-rating catalyst.<\/p><p><strong>Disclaimer: <\/strong>Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information. Verify all numbers before investing. Consult a SEBI-registered financial advisor before making investment decisions.<\/p><p>For more Q4 FY26 results previews, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_When_is_Dr_Lal_Path_Labs_Q4_results_2026_date\"><\/span><strong>Q: When is Dr. Lal Path Labs Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Dr. Lal Path Labs Q4 FY26 results date is May 8, 2026. The board will approve the quarter and full-year FY26 financial results, consider a final dividend, and provide FY27 guidance.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Dr_Lal_Path_Labs_Q4_FY26_revenue_estimate\"><\/span><strong>Q: What is Dr. Lal Path Labs Q4 FY26 revenue estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analyst consensus estimate for Dr. Lal Path Labs Q4 FY26 revenue is Rs 620 Cr. Q3 FY26 actual revenue was Rs 554 Cr. Actual Q4 results may differ based on operating conditions and management execution.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Dr_Lal_Path_Labs_Q4_FY26_PAT_estimate\"><\/span><strong>Q: What is Dr. Lal Path Labs Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analyst consensus estimate for Dr. Lal Path Labs Q4 FY26 net profit (PAT) is Rs 88 Cr. Q3 FY26 actual PAT was Rs 79 Cr. Estimates are indicative and subject to quarterly variance.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_Will_Dr_Lal_Path_Labs_declare_a_dividend_in_Q4_FY26\"><\/span><strong>Q: Will Dr. Lal Path Labs declare a dividend in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Dr. Lal Path Labs is expected to declare Rs 15 for FY26, subject to board approval at the May 8, 2026 meeting and subsequent shareholder approval at the AGM. Verify actual dividend announcement before making any investment decision.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Dr_Lal_Path_Labs_current_share_price\"><\/span><strong>Q: What is Dr. Lal Path Labs current share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Dr. Lal Path Labs is trading at Rs 2,350 as of April 2026 \u2014 down -20% from its 52-week high of Rs 2,950. The 52-week low is Rs 2,050. Track the live price on the Univest Screener.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_were_Dr_Lal_Path_Labs_Q3_FY26_results\"><\/span><strong>Q: What were Dr. Lal Path Labs Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In Q3 FY26, Dr. Lal Path Labs reported revenue of Rs 554 Cr and net profit (PAT) of Rs 79 Cr. Q4 FY26 results on May 8, 2026 will provide the full-year FY26 comparison.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_When_do_TCS_and_Infosys_announce_Q4_results_2026\"><\/span><strong>Q: When do TCS and Infosys announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS declared Q4 FY26 results on April 9, 2026. Infosys is scheduled for April 23, 2026. Both are covered in detail at univest.in\/blogs. Check the earnings calendar table above for other key result dates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_Is_Dr_Lal_Path_Labs_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Q: Is Dr. Lal Path Labs a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This article does not constitute investment advice. Dr. Lal Path Labs at Rs 2,350 trades -20% below its 52-week high of Rs 2,950. Analyst consensus estimates suggest Q4 FY26 revenue of Rs 620 Cr and PAT of Rs 88 Cr. Review the factors, risks, and analyst ratings above. Consult a SEBI-registered financial advisor before making any investment decision.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/balkrishna-industries-q4-results-2026\">Balkrishna Industries Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/balkrishna-paper-mills-q4-results-2026\">Balkrishna Paper Mills Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/balaxi-pharmaceuticals-q4-results-2026\">BALAXI PHARMACEUTICALS Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/balaji-telefilms-q4-results-2026\">Balaji Telefilms Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/balaji-amines-q4-results-2026\">Balaji Amines Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Dr. Lal Path Labs (NSE: LALPATHLAB) is scheduled to declare its Q4 FY26 results on May 8, 2026, when the board of directors will approve the audited financial statements for the January\u2013March 2026 quarter and the full year FY2025\u201326. The stock trades at Rs 2,350 as of April 2026 \u2014 down -20% from its 52-week<\/p>\n","protected":false},"author":27,"featured_media":71082,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3862],"class_list":["post-71079","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results-expectations"],"metadata":{"_edit_lock":["1776163711:27"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:8:{s:62:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-745.jpeg\";a:2:{s:2:\"id\";i:71080;s:11:\"source_type\";s:13:\"media-library\";}s:71:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-745-1024x536.jpeg\";a:2:{s:2:\"id\";i:71080;s:11:\"source_type\";s:13:\"media-library\";}s:94:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155637\/image-745.jpeg\";a:2:{s:2:\"id\";i:71080;s:11:\"source_type\";s:13:\"media-library\";}s:103:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155637\/image-745-1024x536.jpeg\";a:2:{s:2:\"id\";i:71080;s:11:\"source_type\";s:13:\"media-library\";}s:62:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-746.jpeg\";a:2:{s:2:\"id\";i:71081;s:11:\"source_type\";s:13:\"media-library\";}s:71:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-746-1024x536.jpeg\";a:2:{s:2:\"id\";i:71081;s:11:\"source_type\";s:13:\"media-library\";}s:94:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155638\/image-746.jpeg\";a:2:{s:2:\"id\";i:71081;s:11:\"source_type\";s:13:\"media-library\";}s:103:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155638\/image-746-1024x536.jpeg\";a:2:{s:2:\"id\";i:71081;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["77"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":[" Dr. Lal Path Labs Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook"],"rank_math_description":["Dr. Lal Path Labs Q4 FY26 results date is May 8, 2026. Revenue estimate Rs 620 Cr, PAT estimate Rs 88 Cr. Key factors, risks, analyst ratings and share price outlook for 2026.\n"],"rank_math_focus_keyword":["Dr. Lal Path Labs"],"_thumbnail_id":["71082"],"_edit_last":["27"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["8069"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14155714\/Dr.-Lal-Path-Labs-Q4-FY26-Preview.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/71079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=71079"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/71079\/revisions"}],"predecessor-version":[{"id":71097,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/71079\/revisions\/71097"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/71082"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=71079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=71079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=71079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}